Abstract: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: A capsularhexis electrode device and corresponding insertion tool are disclosed. A flexible capsulorhexis electrode device comprises an elastomeric ring, first and second electrically conductive traces disposed at a first face of the elastomeric ring and extending concentrically around the elastomeric ring, and first and second electrically conductive connectors. The first and second electrically conductive connectors are electrically connected to the first and second traces, respectively, and are disposed at opposing points across the elastomeric ring from one another. An insertion tool includes first and second stretcher bars with connectors for mating to the electrode device. One of the stretcher bars translates relative to the other to elongate the flexible electrode device for insertion into the anterior chamber of the eye through a small incision.

Abstract: An irrigation mounting arrangement for an irrigation container that is defined by a body portion, a neck member, and a stopper, is disclosed. The irrigation mounting arrangement comprises an upwardly extending base member and a mounting arm mechanism that extends away from the base member. The mounting arm mechanism includes at least one mounting aperture configured to selectively receive a portion of the irrigation container such that the neck member of the irrigation container is oriented above the body portion.

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

Abstract: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.

Abstract: An implantable intraocular pressure sensor system has a sealed geometric shape with an internal pressure at a first value. The sealed geometric shape has a first light permitting surface and a second flexible surface. A pair of photocells is located in the sealed geometric shape. A light shield is coupled to the second flexible surface. When the second flexible surface is deflected, a light measurement by the pair of photocells indicates an intraocular pressure condition.

Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.

Abstract: The present invention is an ophthalmic injection system with a limited reuse assembly and a tip segment. The tip segment is connectable to and removable from the limited reuse assembly. The tip segment includes a dispensing chamber, a plunger, and a housing. The dispensing chamber holds a quantity of a substance to be injected into an eye. The proximate end of the plunger has a first mechanical linkage interface. The limited reuse assembly of the ophthalmic injection system has a power source, a controller, a motor, a second mechanical linkage interface located on an end of the motor shaft; and a second housing. The first mechanical linkage interface is mateable with the second mechanical linkage interface such that when the tip segment is connected to the limited reuse assembly, the first mechanical linkage interface mates with the second mechanical linkage interface so that motion of the shaft results in motion of the plunger.

Abstract: Pulse-generator circuits that permit independent control of pulse widths and the delays between successive pulses. In several embodiments, a pulse-generator subcircuit includes a transmission-line segment comprising first and second conductors, configured such that the first conductor is coupled to a first DC potential. The pulse-generator subcircuit further includes a terminating resistor coupled to a first end of the second conductor of the first transmission-line segment; this terminating resistor is matched to the characteristic impedance of the transmission-line segment. The pulse-generator subcircuit further includes first and second switches, controlled by first and second timing signals, respectively, and configured to selectively and independently connect respective first and second ends of the first conductor to a second DC potential.

Abstract: A surgical system includes a surgical instrument, an aspiration flow rate measurement device, a vacuum force measurement device, and an indicator. The surgical instrument has an aspiration portion and is located in a media type. The aspiration flow rate measurement device is configured to measure the flow rate generated by the aspiration portion. The vacuum force measurement device is configured to measure the vacuum force generated by the aspiration portion. The indicator provides an indication of the media type in which the surgical instrument is located. The indication is based on aspiration flow rate measurement information, vacuum force measurement information, and an operation and configuration of the surgical instrument.

Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.

Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.

Abstract: The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

Abstract: Disclosed are polyquaternary ammonium polymers containing polyalkylene oxide groups according to formula (I) wherein [A]x, [B]y and [C]z are poly(alkylene oxides) each independently selected from the group consisting of poly(ethylene oxide), poly(propylene oxide), and poly(butylene oxide); Z is selected from the group consisting of —CH2CH?CHCH2—, —CH2CH2CH2CH2—, —CH2—C?C—CH2—, —CH2CH2—O—CH2CH2—, —CH2—N(CH2CH2)2N—CH2—, —CH2CH(OH)CH(OH)CH2— and —CH2—C6H4—CH2—; R is —(CR1R2)mCR3R4— wherein m is an integer from 0 to 3 and R1, R2, R3 and R4 are independently selected from the group consisting of H, CH3 and CH2CH3; n is an integer from 1 to 30; x is either 0 or an integer from 2 to 20; y is an integer from 2 to 20; z is either 0 or an integer from 2 to 20; R? is a branched or unbranched alkyl group having from 1 to 3 carbon atoms and is optionally substituted by one or two hydroxyl groups; Q1 and Q2 are independently selected from the group consisting of —CH2CH?CHCH2—X, —CH2C?C—CH2—X, —N(R?)2, —N(R?)3, —N(R?)(R?),

Abstract: The use of certain urea compounds, for the treatment of retinal disorders associated with pathologic ocular angiogenesis and/or neovascularization is disclosed.

Abstract: An exemplary implantable sensor includes a housing that generally conforms to a curvature of an anterior chamber of a patient's eye. A sensing device disposed in the housing is configured to detect physiological parameters and transmit a signal representing the physiological parameters. The exemplary sensor may be used to detect physiological parameters such as intraocular pressure, flow velocity of aqueous humor, blood sugar, and blood biochemicals.

Abstract: An infusion sleeve, infusion sleeve assembly, and method of making the same are disclosed. An exemplary infusion sleeve assembly may include a tubular body and a tip inserted into the body. The tubular body may include an insertion end and an attachment end. The insertion end may define a tip aperture and a first fluid aperture adjacent the tip aperture, while the attachment end may be configured to be secured to a surgical tool for fluid exchange therewith. The tubular body includes a curved portion between the insertion end and attachment end such that a first axis of the insertion end is angled relative to a second axis of the attachment end. Further, the tubular body may define a substantially smooth surface throughout the curved portion.

Abstract: A phacoemulsification fluidics system for irrigating and aspirating a surgical site includes a sterile solution reservoir, an irrigation path configured to extend from the sterile solution reservoir to the surgical site, and an aspiration path configured to extend from the surgical site. The system also includes a single flow control pump head associated with both the irrigation path and the aspiration path. The flow control pump head is arranged within the system to simultaneously pressurize the irrigation path in a manner that drives the irrigation fluid to the surgical site and pressurize the aspiration path in a manner that vacuums waste fluid from the surgical site.